[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371367-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371367-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multicancer-early-detection-testing-guidance-for-primary-care-discussions-with-patients","Multicancer early detection testing - Guidance for primary care discussions with patients","","Multicancer early detection (MCED) tests represent an emerging cancer screening technology capable of detecting signals from multiple cancers simultaneously in specimens such as blood, urine, saliva, or other bodily fluids. Some assays suggest the most likely cancer origin, while others report that cancer was detected somewhere in the body. Although certain MCED tests are commercially available, none are FDA-approved or endorsed by clinical practice guidelines, coverage remains limited, and randomized trial evidence for safety and effectiveness is lacking. Clinicians should discuss known benefits, risks, uncertainties, performance in screening populations, and preferred follow-up after positive results, supporting shared decision-making.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multicancer-early-detection-testing-guidance-for-primary-care-discussions-with-patients/371367/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multicancer-early-detection-testing-guidance-for-primary-care-discussions-with-patients/371367.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What do multicancer early detection (MCED) tests detect?","Question",{"text":63,"@type":64},"MCED tests detect cancer signals from multiple cancers concurrently using biological samples such as blood, urine, saliva, or other bodily fluids.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Are MCED tests FDA-approved and endorsed by clinical guidelines?",{"text":68,"@type":64},"As of November 2024, no MCED tests have been approved by the FDA, and none are endorsed by any clinical practice guideline or recommendation.",{"name":70,"@type":61,"acceptedAnswer":71},"How should clinicians handle patient requests for MCED testing results?",{"text":72,"@type":64},"Clinicians should engage in shared decision-making when patients inquire about testing or interpretation of previous results, discussing benefits, risks, uncertainties, and preferred follow-up strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371367,1790289344,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1002/cncr.35823  \nCONSENSUS STATEMENT  \nMulticancer early detection testing: Guidance for primary care discussions with patients  \nRichard M. Hoffman MD, MPH1  | Andrew M. D. Wolf MD2 |  \nSana Raoof MD, PhD3  | Carmen E. Guerra MD, MSCE4 | Timothy R. Church PhD5 | Elena B. Elkin PhD, MPA6 | Ruth D. Etzioni PhD7 | Ya-Chen Tina Shih PhD8 |  \nSteven J. Skates PhD9 | Deana Manassaram-Baptiste PhD, MPH10 | Robert A. Smith PhD10   \n1Department of Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA 2Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA 3Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA  \n4Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  \n5Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA 6Department of Health Policy and Management, Columbia University Mailman School of Public Health, New York, New York, USA  \n7Public Health Sciences Division, Department of Biostatistics, Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington, USA 8Department of Radiation Oncology, Department of Health Policy & Management, Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA  \n9Department of Medicine, MGH Biostatistics, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA 10Center for Early Cancer Detection Science, American Cancer Society, Atlanta, Georgia, USA  \nCorrespondence  \nRichard M. Hoffman, Carver College of Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, IA 52242, USA.  \nEmail: [richard-m-hoffman@uiowa.edu](richard-m-hoffman@uiowa.edu)  \nAbstract  \nMulticancer early detection (MCED) tests are an emerging technology for cancer screening. MCED tests can detect cancer signals from multiple cancers concurrently in biological samples such as blood, urine, saliva, or other bodily fluids. Some tests can suggest the most likely cancer origin, whereas others report cancer detected somewhere in the body. Although some MCED tests are currently commercially available, none are approved by the Food and Drug Administration or endorsed by any clinical practice guideline or recommendation. Most insurance companies do not currently cover MCED testing. MCED tests have not yet been evaluated for safety and effectiveness in randomized controlled trials. Because patients already areasking for MCED test prescriptions or for interpretation of results from tests acquired elsewhere, clinicians should be prepared to discuss what is known about the benefits, risks, and uncertainties of MCED testing, including performance characteristics in screening populations and preferred follow-up strategies for positive test results. At this time, clinicians should not feel obligated to initiate discussions about  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2025 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2025;e35823.  \n[https://doi.org/10.1002/cncr.35823](https://doi.org/10.1002/cncr.35823)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 10  \nMCED testing with their patients. However, clinicians should engage patients who inquire about getting tested or previous MCED test results in shared decisionmaking, and take the opportunity to offer and help patients complete age- and sex-appropriate guideline-recommended cancer screenings. In this article, the current evidence and issues around MCED testing are summarized, and a framework for shared decision-ma","cbCailuYfFN3TAFb","https://ap.wps.com/l/cbCailuYfFN3TAFb","pdf",282030,"English","# Introduction\n## Multicancer early detection (MCED) tests as liquid biopsies\n## Detection signals and biomarker analysis\n## Regulatory status and clinical evidence","[{\"question\":\"What do multicancer early detection (MCED) tests detect?\",\"answer\":\"MCED tests detect cancer signals from multiple cancers concurrently using biological samples such as blood, urine, saliva, or other bodily fluids.\"},{\"question\":\"Are MCED tests FDA-approved and endorsed by clinical guidelines?\",\"answer\":\"As of November 2024, no MCED tests have been approved by the FDA, and none are endorsed by any clinical practice guideline or recommendation.\"},{\"question\":\"How should clinicians handle patient requests for MCED testing results?\",\"answer\":\"Clinicians should engage in shared decision-making when patients inquire about testing or interpretation of previous results, discussing benefits, risks, uncertainties, and preferred follow-up strategies.\"}]","Multicancer early detection testing - Guidance for primary care discussions with patients | PDF",1790191911,25]